These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 8041120)

  • 1. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.
    O'Malley FP; Vnencak-Jones CL; Dupont WD; Parl F; Manning S; Page DL
    Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias.
    Done SJ; Arneson NC; Ozçelik H; Redston M; Andrulis IL
    Cancer Res; 1998 Feb; 58(4):785-9. PubMed ID: 9485035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 mutations and histological type of invasive breast carcinoma.
    Marchetti A; Buttitta F; Pellegrini S; Campani D; Diella F; Cecchetti D; Callahan R; Bistocchi M
    Cancer Res; 1993 Oct; 53(19):4665-9. PubMed ID: 8402644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of p53 mutations in bilateral breast carcinoma.
    Ackerman J; Baunoch DA; Gimotty P; George J; Lane MA; Dawson PJ
    Mod Pathol; 1995 Apr; 8(3):244-8. PubMed ID: 7617647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 Gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques.
    Hurlimann J; Chaubert P; Benhattar J
    Mod Pathol; 1994 May; 7(4):423-8. PubMed ID: 8066070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microvessel density, proliferating activity, p53 and bcl-2 expression in in situ ductal carcinoma of the breast.
    Zolota V; Gerokosta A; Melachrinou M; Kominea A; Aletra C; Scopa CD
    Anticancer Res; 1999; 19(4B):3269-74. PubMed ID: 10652623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 alterations in chemically induced hamster cheek-pouch lesions.
    Gimenez-Conti IB; LaBate M; Liu F; Osterndorff E
    Mol Carcinog; 1996 Aug; 16(4):197-202. PubMed ID: 8784462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. bcl-2 expression in the spectrum of preinvasive breast lesions.
    Siziopikou KP; Prioleau JE; Harris JR; Schnitt SJ
    Cancer; 1996 Feb; 77(3):499-506. PubMed ID: 8630957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer.
    Bhargava V; Thor A; Deng G; Ljung BM; Moore DH; Waldman F; Benz C; Goodson W; Mayall B; Chew K
    Mod Pathol; 1994 Apr; 7(3):361-8. PubMed ID: 8058709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The timing and characterization of p53 mutations in progression from atypical ductal hyperplasia to invasive lesions in the breast cancer.
    Kang JH; Kim SJ; Noh DY; Choe KJ; Lee ES; Kang HS
    J Mol Med (Berl); 2001 Nov; 79(11):648-55. PubMed ID: 11715068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible association of p53 overexpression and mutation with high-grade chondrosarcoma.
    Dobashi Y; Sugimura H; Sato A; Hirabayashi T; Kanda H; Kitagawa T; Kawaguchi N; Imamura T; Machinami R
    Diagn Mol Pathol; 1993 Dec; 2(4):257-63. PubMed ID: 8118603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
    Naidu R; Wahab NA; Yadav MM; Kutty MK
    Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical analysis of p53 expression in primary breast carcinomas.
    Naidu R; Yadav M; Nair S; Kutty KK
    Anticancer Res; 1998; 18(1A):65-70. PubMed ID: 9568057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas.
    Weyrer K; Feichtinger H; Haun M; Weiss G; Ofner D; Weger AR; Umlauft F; Grünewald K
    Lab Invest; 1996 Jan; 74(1):279-89. PubMed ID: 8569192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction.
    Naidu R; Wahab NA; Yadav M; Kutty MK
    Int J Mol Med; 2002 Feb; 9(2):189-96. PubMed ID: 11786932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
    Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
    Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China.
    Gao H; Wang LD; Zhou Q; Hong JY; Huang TY; Yang CS
    Cancer Res; 1994 Aug; 54(16):4342-6. PubMed ID: 8044781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
    Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes.
    Maxhimer JB; Pesce CE; Stewart RA; Gattuso P; Prinz RA; Xu X
    J Am Coll Surg; 2005 Mar; 200(3):328-35. PubMed ID: 15737842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.